S12 Ep7: Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
In today’s episode, supported by Amgen, we had the pleasure of speaking with Ryan Cassaday, MD, an associate professor in the Clinical Research Division at the Fred Hutchinson Cancer Center and an associate professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle, Washington.
In our exclusive interview, Dr Cassaday discussed insights from several trials investigating blinatumomab (Blincyto) in patients with B-cell acute lymphoblastic leukemia (B-ALL) that were reported at the 2024 ASH Annual Meeting, including subgroup analyses of the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.